Jean-Pierre Muratet

Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.

Jean-Pierre Muratet, A Daver, J Minier et al. · PubMed · 1998 · 116 citations

Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by ¹⁸F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study)

Pierre Véra, S. Thureau, Philippe Chaumet‐Riffaud et al. · Journal of Nuclear Medicine · 2017 · 81 citations · Full text

Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.

Jean-Pierre Muratet, P. Giraud, A Daver et al. · PubMed · 1997 · 70 citations

Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer

Marie‐Odile Bernier, Olivier Morel, Patrice Rodien et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2005 · 55 citations

Medicine, Prognostic Value, Thyroid Disease +10

Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics

Janita E. van Timmeren, Sara Carvalho, Ralph T. H. Leijenaar et al. · PLoS ONE · 2019 · 48 citations · Full text